Related Experiment Video
Updated: Jun 11, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Current and future use of intravenous thrombolysis for acute ischemic stroke
1St. Luke's Roosevelt Hospital Center, 1000 10th Avenue, New York, NY 10019, USA. lelijovich@chpnet.org
Abstract:
Stroke is a common and disabling condition. Intravenous tissue plasminogen activator (tPA) administered within 3 h of symptom onset is the standard therapy for eligible patients with acute ischemic stroke. Unfortunately, because of the time limitation, very few patients with ischemic stroke actually receive this treatment. In order to increase the number of patients who may benefit from acute treatment, recent research has focused on expanding the time window for thrombolysis and improving its efficacy to ultimately improve patient outcome.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Ischemic Stroke ll: Pathophysiology
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Ischemic Stroke l: Introduction

